Prognostic factors for progression-free survival in prospective clinical trials on reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (alloSCT) in chronic lymphocytic leukemia (CLL).
| . | Dreger et al16 . | Sorror et al15 . | Brown et al24 . | Khouri et al25 . | Schetelig et al13 . | Delgado et al36 . |
|---|---|---|---|---|---|---|
| – indicates not significant; ++, significantly predicting adverse outcome; n.i., not investigated. | ||||||
| *Tested by univariate analysis only | ||||||
| aPrognostic factors for progression | ||||||
| bLymphadenopathy > 5 cm at SCT | ||||||
| cdel 17p- | ||||||
| ddel 17p-, del 11q-, or complex | ||||||
| n | 90 | 82 | 46 | 39 | 30 | 41 |
| Age | – | –* | – | –* | n.i. | – |
| Unrelated donors | – | –* | –* | –* | –* | –* |
| High number of pretreatment lines | n.i. | – | ++ | –* | –* | –* |
| Purine analogue refractoriness | – | – | n.i. | n.i. | –* | ++ |
| Unresponsive disease at SCT | ++ | ++ b | ++ | ++ | –* | –* |
| Cytogenetics unfavorable | –c | –d* | –d | n.i. | n.i. | n.i. |
| . | Dreger et al16 . | Sorror et al15 . | Brown et al24 . | Khouri et al25 . | Schetelig et al13 . | Delgado et al36 . |
|---|---|---|---|---|---|---|
| – indicates not significant; ++, significantly predicting adverse outcome; n.i., not investigated. | ||||||
| *Tested by univariate analysis only | ||||||
| aPrognostic factors for progression | ||||||
| bLymphadenopathy > 5 cm at SCT | ||||||
| cdel 17p- | ||||||
| ddel 17p-, del 11q-, or complex | ||||||
| n | 90 | 82 | 46 | 39 | 30 | 41 |
| Age | – | –* | – | –* | n.i. | – |
| Unrelated donors | – | –* | –* | –* | –* | –* |
| High number of pretreatment lines | n.i. | – | ++ | –* | –* | –* |
| Purine analogue refractoriness | – | – | n.i. | n.i. | –* | ++ |
| Unresponsive disease at SCT | ++ | ++ b | ++ | ++ | –* | –* |
| Cytogenetics unfavorable | –c | –d* | –d | n.i. | n.i. | n.i. |